Groupama Asset Managment Sells 22,742 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Groupama Asset Managment cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 67,870 shares of the biopharmaceutical company’s stock after selling 22,742 shares during the period. Groupama Asset Managment owned about 0.06% of Regeneron Pharmaceuticals worth $35,360,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. PGGM Investments grew its stake in shares of Regeneron Pharmaceuticals by 159.7% during the second quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after acquiring an additional 51,900 shares during the last quarter. Founders Capital Management LLC lifted its stake in Regeneron Pharmaceuticals by 7.0% during the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock valued at $4,344,000 after acquiring an additional 538 shares during the period. Sepio Capital LP boosted its holdings in Regeneron Pharmaceuticals by 33.1% in the first quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock valued at $2,150,000 after purchasing an additional 842 shares during the last quarter. Generate Investment Management Ltd acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $6,300,000. Finally, Bellecapital International Ltd. grew its holdings in Regeneron Pharmaceuticals by 32.7% during the second quarter. Bellecapital International Ltd. now owns 25,503 shares of the biopharmaceutical company’s stock worth $13,389,000 after acquiring an additional 6,283 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.3%

Shares of NASDAQ:REGN opened at $784.61 on Friday. The company’s fifty day moving average is $631.01 and its two-hundred day moving average is $582.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $800.99. The stock has a market capitalization of $82.46 billion, a price-to-earnings ratio of 18.79, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter last year, the company earned $12.46 EPS. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at $1,538,843.04. This trade represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. The trade was a 9.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on REGN shares. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a report on Wednesday, October 29th. Royal Bank Of Canada raised their price objective on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a research note on Wednesday, October 29th. Sanford C. Bernstein raised their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Morgan Stanley reduced their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Finally, Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They set a “buy” rating and a $890.00 price objective for the company. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $757.91.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.